GIGABYTE
5.1.2023 19:01:39 CET | Business Wire | Press release
GIGABYTE, a leading supplier of computer hardware and pioneer in the tech industry, presents “Power of Computing” at CES 2023 to demonstrate exceptional computing prowess that drives innovative technologies forward. An extensive range of enterprise and personal computer solutions are brought to the show to resonate with the theme.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230105005713/en/
GIGABYTE at CES 2023: Power of Computing to Reshape the World (Photo: Business Wire)
- Data Center Servers: Computing breakthroughs that propel next-gen technologies and AI applications.
- Advanced Cooling Solutions: Computing performance and environmental sustainability in harmony.
- Mobile Computing Platforms: Zonal computing to enable a safer and greener transportation.
- PCs and Laptops: Next-gen performance delivered for digital natives.
Data Center is an integral part of making technological breakthroughs. GIGABYTE has always been trusted as a pioneer in developing new server products for developers, and worked on software integrations to provide product solutions that are in line with the future of the digital age. GIGABYTE brought to CES its next-gen server hardware and computing technology that unleashes greater performance, improved energy efficiency, and is ready for high-density compute with the latest CPUs and GPUs to accelerate workloads of any scale. Also showcased is an enterprise-grade workstation that coupled with MyelinTek’s ready-to-go MLOps AI development environment. The MLOps’s easy-to-use interface enables engineers to quickly train AI models suited for their innovations, and the workstation’s outstanding performance allows a painless implementation.
Computing demands are facing a thermal dilemma in which performance gain is at environment’s sacrifice. GIGABYTE’s Air, Liquid, and Immersion Cooling Solutions are specially designed to increase heat dissipation efficiency, empowering servers to deliver exceptional high performance while lowering carbon emissions, paving the way for a sustainable future without sacrificing economic growth. At its CES booth GIGABYTE also debuts TO15-Z40, which is an OCP server compatible with all major immersion tanks, to show the most future-proof computing to industry leaders who wish to create a balance in tech advancements and environmental sustainability.
Vehicle tech is thriving as it leverages the power of computing to helm artificial intelligence and communications, therefore paving way for safer driving and smarter traffic. With extensive experience in developing ADCU (Autonomous Driving Control Unit) and ADAS DCU (Domain Control Unit), GIGABYTE provides the automotive industry with high-performance Zonal Integrated DCUs and decision-making control hosts, which are built with a centralized architecture and can be integrated into various requirements and design concepts, lowering vehicle production costs.
GIGABYTE launched its newest iteration of AERO creator laptops and AORUS gaming laptops just in time before CES begins. Both laptops series are built with 13th gen Intel® Core™ processors and NVIDIA RTX™ 40 series graphics cards, and in addition, are designed with the latest technologies, to present tech fanatics with computing performance that exceeds their expectations. The newly crowned CES 2023 Innovation Award winner, Stealth 500 PC DIY Kit, and a whopping 48” gaming monitor are also showcased for users to feast their eyes on.
Visit GIGABYTE ‘Power of Computing’ event page
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005713/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 18:26:00 CEST | Press release
Founding partners Beroe, Keelvar and Zip bring back the community-driven event with a practitioner-shaped agenda spanning real-world AI use and the future of procurement ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, fru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom